The BioCentury London index fell 7% last quarter, driven mainly by a 21% decline in the market value of BTG plc (LSE:BTG) to £1.1 billion ($1.7 billion). In August, BTG partner AstraZeneca plc (LSE:AZN; NYSE:AZN) discontinued development of AZD9773 (CytoFab) after the compound failed in a Phase IIb sepsis trial